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Abstract
Lung transplantation is the treatment of choice for end-stage pulmonary diseases. A
limited donor supply has resulted in 4000 patients on the waiting list. Currently, 10-20%
of donor organs offered for transplantation are deemed suitable under the selection
criteria, of which 15-25% fails due to primary graft dysfunction (PGD). This has resulted
in increased efforts to search for alternative donor lungs selection criteria. In this study,
we attempt to further our understanding of PGD by observing the changes in gene
expression across donor lungs that developed PGD versus those that did not. Our second
goal is to use a machine learning tool - support vector machine (SVM), to distinguish
unsuitable donor lungs from suitable donor lungs, based on the gene expression data.
From our analysis, we have obtained transcripts that were involved in signalling,
apoptosis and stress-activated pathways. Results also indicate that metallothionein 3 may
prevent lungs from developing PGD. Preliminary classification results for distinguishing
suitable and unsuitable lungs for transplantation using a SVM were promising. This is the
first such attempt to use human lungs used for transplantation and combine the
identification of a molecular signature for PGD, with machine learning methods for
donor lung prediction.

Introduction
Lung transplantation has gained widespread acceptance for the treatment of end-stage
pulmonary diseases. However, two significant problems in clinical lung transplantation
are a major shortage of donor organs and the incidence of primary graft dysfunction
(PGD). PGD is a severe allograft ischemia-reperfusion (I/R) injury syndrome occurring
in the hours following transplantation. It significantly affects morbidity as well as early
and late mortality. Improvements in operative techniques, donor lungs management, and
immunosuppressive protocols have decreased perioperative mortality to below 10% at
most experienced lung transplant centres (1, 2). The one- and five-year survival rates
have improved to 76% and 49%, respectively (1). These results, however, continue to lag
behind those achieved for other solid organ transplants. The occurrence of PGD after
lung transplantation significantly increases the duration of mechanical ventilation,
hospital length of stay and short-term mortality after lung transplantation (3). Survivors
of PGD have a significantly protracted recovery with impaired physical function up to
one year after transplantation and an increased risk of death extending beyond the first
year after transplantation (3, 4).
The current criteria used to evaluate potential donor lungs appear to be inadequate at
predicting how these lungs will function post-transplantation (5, 6, 7). Donor organs are
evaluated for lung transplantation on the basis of criteria that are primarily historically
founded and largely arbitrary (8). Relatively crude measures of lung function such as
chest radiography, arterial oxygen tension in blood gases, and bronchoscopy are currently
used to assess the quality of potential donor lungs. That these tools are inadequate in
evaluating organs from prospective donors is evidenced by two recent developments.
First, the liberalisation of the selection criteria and the use of ‘marginal’ donor lungs by
many centres have not had a negative impact on outcome after transplantation (9-11). A
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recent study showed no significant difference in a number of indices for infection and
inflammation between donor lungs that were accepted and rejected for transplantation
(7). Second, the incidence of PGD or I/R injury, after transplantation remains unchanged
at 15-25% despite the increased use of marginal donor lungs and improvements in all
areas
of
lung
transplantation
(2,
4,
12).
These issues have led investigators to search for criteria that may subject lungs to
increased risk of PGD. While recent studies have identified donor age and recipient
diagnosis of primary pulmonary hypertension (PPH) as risk factors for the development
of PGD, the aetiology of PGD in most cases after transplantation is unknown and thought
to be due to complex interactions between donor lung and recipient immune system (13,
14).
A limited donor supply has dramatically increased the waiting time for transplant
recipients. Approximately 4,000 patients are currently on the transplant waiting list and
this has resulted in intense pressure to search for alternative strategies. Unfortunately, up
to 10-20% of these patients on the waiting list will die from their underlying lung disease
before an organ becomes available. Currently, only 10-20% of cadaveric donor organs
offered for transplantation are judged to be acceptable under the current selection criteria
(15).
More biologically meaningful donor lungs selection criteria may result in
significant expansion of the number of lungs accepted from this potential donor pool (5).
The results of the above mentioned studies suggest that there may be complex, occult
biological factors present in donor lungs which contribute to the development of PGD
that are not detected by the current donor organ evaluation. Gene expression profiling is a
powerful, high-performance tool of molecular biology that allows the analysis of the
levels of expression of thousands of genes simultaneously. It has been previously used to
study gene transcripts involved in I/R injury using a rat model (16). To the best of our
knowledge, however, this is the first report where gene expression profiling has been
used on actual human lungs used for transplantation, along with the application of
machine learning techniques to attempt to distinguish unsuitable donor lungs from
suitable donor lungs.
Our objective is two fold - the first is to obtain a set of genes involved in PGD and
identify new gene products relevant to allograft transplantation; and the second is to use
this set of genes for classification of donor lungs into PGD positive (i.e. lungs that
develop PGD) or PGD negative (i.e. lungs that do not develop PGD) categories. The first
objective would provide greater insights into the mechanisms of PGD as well as extend
the work of Yamane et al (16). The set of genes identified as being involved in PGD can
be designated as the ‘molecular signature’ of PGD. As many donor lungs that may be
actually suitable for transplantation, are discarded by the current selection criteria, it
would be useful to classify unseen donor lungs, using the molecular signature derived in
the first objective coupled with machine learning techniques. Such a classification can
ultimately perhaps increase the potential donor pool for lung transplantation and is the
motivation behind our second objective.
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Materials and Methods
Donor lung sampling
From August 2003 to January 2005, 80 transplants were performed in our programme at
Washington University School of Medicine. Three of these were excluded from the
study as one was a single lung transplant, another was a heart-lung transplant, and the
third was a combined coronary artery bypass graft with lung transplant. This resulted in
biopsies of 77 donor lungs used for bilateral sequential lung transplantation. The biopsies
were obtained from the anterior right middle lobe or lingula immediately prior to coldflushing. Of these 77, 9 patients did not give consent. Of the remaining biopsies, some
samples were excluded due to technical errors or complexities during expression
profiling, resulting in a net total of 50 biopsies being used for the study. Five lungs were
considered marginal donor lungs based on them portraying one or more of the following
conditions - either PaO2 in arterial blood gas < 300 on 100% inspired oxygen, or smoking
history > 20 pack-years or donor age > 55. These samples were immediately snap-frozen
in liquid nitrogen and then stored in a -70° Celsius freezer until used for analysis.
Specimens were sampled using standard techniques for open lung wedge biopsy. An area
of lung tissue approximately 1 x 1 cm was isolated and excised using 2 staple lines from
a 30 mm EndoGIA stapler (US Surgical, Norwalk, CT). This protocol was approved by
the Human Studies Committee and Institutional Review Board at Washington University
School of Medicine and protection of human subjects, namely recipients, was afforded by
detailed informed consent before entrance into this research protocol. No complications
related to sampling of the donor lungs occurred in this study. As this is a pilot study done
on actual human lungs used for transplantation, we did not have enough tissue to perform
RT-PCR.
RNA Isolation
Single isolates of donor lung samples were homogenised in the presence of RNAzolB
and finally dissolved in RNase-free H2O. 25 g of total RNA was treated with DNase
using the Qiagen RNase-free DNase kit and samples were further purified using RNeasy
spin columns (Qiagen, Valencia, CA). Total RNA treated with DNase was dissolved in
RNase-free H2O to a final concentration of 0.2 g/l. RNA quality was assessed by 1%
agarose gel electrophoresis in the presence of ethidium bromide. Samples that did not
reveal intact and approximately equal 18S and 28S ribosomal bands were excluded from
further study.
cDNA Synthesis and Gene Expression Profiling
This study used commercially available high-density microarrays (Affymetrix, Santa
Clara, CA) that produce gene expression levels on 22,278 probe sets (Affymetrix Human
Genome U133Av2.0 Array). Each donor lung biopsy was analysed on a different
GeneChip. Preparation of cDNA, hybridisation, and scanning of the arrays were
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performed according to the manufacturer's instructions. The arrays were scanned using
the Affymetrix GeneArray scanner. Image analysis was performed with the Affymetrix
GeneChip software. We also performed a quality control test on the dataset using the R
package ‘affyQCReport’ (17) and the results were favourable.
Data
The data from all 50 gene chips was normalised using the GCRMA method developed by
(18). The 50 donor lung samples were divided into two groups - those that developed
PGD after transplantation (PGD positive) and those that did not (PGD negative). PGD
was defined as T0 Grade III dysfunction according to International Society for Heart and
Lung Transplantation criteria, that is, a ratio (referred to as the P/F ratio) of partial
pressure of arterial oxygen (PaO2) to fraction of inspired oxygen (FiO2) less than 200 in
the first arterial blood gas in the intensive care unit after transplantation (generally 4-6
hours after actual reperfusion) (19). Although definitions of PGD at later time points
may more accurately reflect outcomes after transplantation, they may also be potentially
affected by other postoperative factors such as overall fluid balance or presence of
infection. Sixteen samples were classified as PGD positive according to this definition
and the remaining thirty-four were PGD negative.
Transcripts Selection
We then proceeded to the next step in our study - the identification of differentially
expressed (DE) transcripts. The objective was to find a set of DE transcripts/probes that
could be used as a molecular signature for the condition. DE transcript extraction falls
into two broad categories - wrapper methods and filter methods. In wrapper transcript
selection methods, the DE transcript identification phase is integrated with the
classification phase. In filter methods, the DE transcript extraction phase is independent
of the classification phase. In this study, we used two packages for the identification of
DE transcripts - RankGene (20), and significance analysis of microarrays (SAM) (21).
RankGene is a programme for analysing gene expression data, feature selection and
ranking genes based on the predictive power of each gene/transcript to classify samples
into functional or disease categories. It supports eight different measures for quantifying
a gene's ability to distinguish between classes. For our analysis, we used the t-statistics
measure of predictability. The t-statistic value is a score for each gene’s ability to
discriminate between the 2 classes. RankGene ranks genes according to the decreasing
order of the absolute value of the t-statistic for each gene. The group of top genes from
this ranked list is considered to be the most informative for distinguishing between the
classes. SAM is open-source software which identifies DE genes based on the change in
gene expression relative to the standard deviation of repeated measurements (21). It uses
the false discovery rate (FDR) and q-value method presented in (22) to select genes. As
microarrays result in the measurement of several thousand probes, the individual p-values
are not a good measure of significance. The q-value is used to adjust for multiple testing.
It is analogous to the p-value and is corrected, through a permutation process, for the
variability of the expression data. The q-value of a transcript is the FDR for the transcript
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list that includes that transcript and all transcripts that are more significant. SAM also
provides the tail strength (TS) value which measures the deviation of each p-value from
its expected value. Therefore, large positive TS values indicate evidence against the null
hypothesis, i.e., there are more small p-values than one would expect by chance (23).
We first ran RankGene on the complete set of probes. Since we were interested in the
most highly DE transcripts, we chose to take the top 100 transcripts from the ranked list
for further analysis. On this list of 100 DE transcripts, we applied SAM. SAM displayed
81 differentially expressed transcripts based on a FDR of 0% and a TS of 92.7%. After
averaging the values of and removing multiple probes mapping to the same gene name,
23 upregulated and 42 downregulated transcripts were obtained. These sets of up and
down regulated transcripts were used for further analysis in Ingenuity Pathway Analysis
software.
Pathway analysis
Ingenuity Pathway Analysis (IPA) (www.ingenuity.com) was used to perform pathway
analysis on the two sets of DE transcripts - upregulated and downregulated, to identify
networks of genes that are known to interact functionally. IPA uses the Ingenuity
Pathways Knowledge Base (IPKB) which contains large amounts of individually
modelled relationships between objects (e.g., genes, proteins and mRNAs) to
dynamically generate significant biological/gene expression networks and pathways. The
identified DE transcripts from our analysis that are mapped onto the IPKB are called
‘focus genes’. These are used as starting points for building the networks. IPA consists
of genes that have functions assigned to them and are in published literature. First, IPA
queries the IPKB for interactions between the focus genes and all other genes stored in
IPKB and then generates a set of networks/pathways with a maximum of 35 genes. A p
value for each network is calculated according to the user's list of DE genes. This is
accomplished by comparing the number of focus genes that are present in a given
pathway, relative to the total number of occurrences of those genes in all pathways stored
in IPKB. The score of the network is shown as the negative logarithm of the p value,
indicating the likelihood of the focus genes in a network being found together by random
chance. In our study, we further analysed networks that had a network score of 10 or
higher. If genes do not have any known functions assigned to them, they do not become
focus genes in IPA although they have a gene name. This network analysis is an
exploratory in silico approach and does not necessarily indicate that the pathway or
network actually exists.
Support Vector Machines
Originally developed by Vapnik (24), the support vector machine (SVM) is a statistical
learning tool which has been extensively used for binary classification with great success.
Ranging from classification of cancer (25) to determination of haemodialysis dosage
(26), SVMs have proven to be an effective tool in a wide-range of applications.
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SVM was used for the classification of patient samples into PGD positive or PGD
negative categories. The dataset consisted of 50 patient samples and 100 transcripts
(ranked transcripts from RankGene). Following is the manner in which SVM was used.
The dataset is divided into training and test (unseen by the classifier) sets. The test set is
also the validation set because although the user knows the classes of the samples in the
test set, the classifier does not see the samples in the test set while it is training. The SVM
is trained on the training set. The classifier performance is measured by the prediction
accuracy on the test set. It is quite well known that the set of significant genes (SG) from
a particular set of training data is very often very different from one chosen from a
different set of training data. Obtaining a SG set from the complete dataset (i.e. from all
50 patient samples), leads to a selection bias. In order to avoid selection bias, an external
cross-validation (CV) was performed i.e. the classifier performance was measured using
only the set of genes (i.e. a subset of the 100 transcripts) obtained from the training set
and not from the complete dataset of 50 patients. Ten fold CV was carried out rather than
leave-one-out (LOO) CV, as the variability in the list of SG is much lower with 10 fold
CV and this is what is preferred. Results were averaged over 20 runs.

Results and Discussion
The definition of PGD used in this study was T0 Grade III PGD as described by the
International Society for Heart and Lung Transplantation consensus statement on the
definition of primary graft dysfunction (19). In this statement, any time between
immediately post-transplant (T0, ideally defined as arrival in the ICU, within 6 hours
post-reperfusion) and 72 hours after transplantation (T72) can be used to measure blood
gases and define PGD. Although definitions of PGD at later time points may more
accurately reflect outcomes after transplantation, they may also be potentially affected by
other postoperative factors such as overall fluid balance or presence of infection. Our
objective in this study was to identify biologic risk factors in donor lungs that may
contribute to PGD and therefore we felt that this was most purely measured at T0, where
lung function may most clearly reflect the status of the donor lung at the time of harvest.
Furthermore, data from our institution suggests that PGD as early as T0 is associated with
the development of bronchiolitis obliterans syndrome (chronic rejection) (27).
The characteristics of the donor lungs are depicted in Table 1. The operative factors and
the outcome of patients with PGD versus those without are shown in Table 2 and Table 3,
respectively. Despite other studies correlating donor age and recipient diagnosis of PPH
with PGD, we have not seen a significant correlation in our samples. Although,
cardiopulmonary bypass (CPB) seemed to be significant, it could also occur as a result of
PGD rather than be a causative factor of PGD.
SAM analysis resulted in 81
differentially expressed (DE) transcripts which resolved into 65 unique genes using
DAVID (http://niaid.abcc.ncifcrf.gov/tools.jsp) at the time of writing this paper. This list
along with the fold change is presented in Table 4. A flowchart depicting the sequence of
analysis is shown in Figure 1.

6

Pathways and gene products involved in PGD:
The upregulated transcripts were analysed using the Ingenuity Pathway Analysis (IPA)
software. There were 23 upregulated transcripts, of which 13 were focus genes. Focus
genes are the genes that map onto the Ingenuity Pathways Knowledge Base (IPKB). The
network generated from these genes is shown in Figure 2.
Network 1 primarily centres on tumour protein p53 (TP53). The focus genes are shown
in shaded/solid shapes and more details on these nodes are given in the supplementary
material (Table 1). Figure 3 shows the location of the different gene products and the
canonical pathways present in Network 1. The legend for the network is shown in Figure
7. It is natural to expect many pathways related to apoptosis and cell signalling as over
50% of the donor lungs (PGD positive and PGD negative) were involved in some kind of
trauma. Interestingly, a few transcripts identified are also cancer related genes. There is
growing evidence of genetic parallels between lung development and several types of
cancer (28, 29). The authors of (30) have shown that Wnt signalling, cell cycle, and
apoptosis pathways play important roles in lung development. We also have noticed an
increased presence of genes in these pathways in our study (Figure 3).
Next, we analysed the 42 downregulated transcripts using IPA, and obtained 11 focus
genes. The network created from these 11 genes is shown in Figure 4. Network 2 shows
a lot of activity around beta-5 integrin (ITGB5) and GRB2-associated binding protein 2
(GAB2). The focus genes are shown in shaded/solid shapes and further description of
these nodes are given in the supplementary material (Table 2). Figure 5 shows the
location of the different gene products and the canonical pathways present in Network 2.
The legend for the network is shown in Figure 7. We observe similar pathways, as the
ones present in Network 1, in Network 2. This is not unexpected since a pathway can
consist of up and downregulated genes.
Both the networks show the presence of nuclear factorKB (NFKB), stress-activated
protein kinases NH2-terminal Jun kinase (SAPK/JNK) and p38 mitogen-activated protein
kinase (MAPK) signalling pathways. NFKB plays a vital role in mediating immune and
inflammatory responses, and apoptosis. It regulates the expression of a large number of
genes. Many of the gene products regulated by NFKB in turn activate NFKB, such as
vascular endothelial growth factor (VEGF), and receptor for advanced glycation end
product (RAGE). Activation of NFKB involves the phosphorylation-induced,
proteasome-mediated degradation of the inhibitory subunit - inhibitory protein KB. This
protein is phosphorylated by an upstream serine kinase, which, in turn is phosphorylated
and activated by additional upstream serine kinases. SAPK/JNK are members of the
superfamily of MAP serine/threonine protein kinases. This family also includes p38
MAP kinases (p38 MAPK) and extracellular signal-related kinases (ERK) (31).
JNK/SAPK and p38 MAPK are known as stress-activated kinases, and are responsive to
numerous exogenous and endogenous stress-inducing stimuli, such as reactive oxygen
species (ROS), oxidative stress, osmotic stress, proinflammatory cytokines, heat shock,
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and ultraviolet irradiation. Oxidative stress is defined as a persistent imbalance between
the production of highly reactive molecular species (primarily oxygen and nitrogen) and
antioxidant defences, finally resulting in tissue damage. There is evidence in literature
that NF-KB, SAPK/JNK and p38 MAPK signalling pathways are stress-sensitive
intracellular signalling systems, activation of which results in the increased expression of
numerous gene products that cause cellular damage (32).
Gene products associated with stress-activated pathways emerged from both our study as
well as the study in the rat model for ischemia-reperfusion injury (16). As the
experimental protocol, and animal model are different, one would not expect too much of
an overlap. As suggested by the recent articles in Nature Biotechnology by the
MicroArray Quality Control (MAQC) project (33), it is better to focus on pathways and
broad functional relationships, rather than on individual genes. They state that “even
under the best circumstances, gene lists will still differ somewhat from person to person
and place to place”. In our work, we have observed a good deal of overlap in the
functional categories/pathways of the identified transcripts. As not all animal model
studies translate well into human analysis, our investigation takes the study performed by
(16) a step further by performing the analysis on human samples and showing consensus.
An exciting observation was that the metallothionein family of gene products was
identified as being upregulated in the lungs that did not develop PGD. In the work by
Yamane et al (16), metallothionein levels of expression are much lower in the microarray
when compared to most of the other genes considered significant. However, RT-PCR
confirms that it does have an increased expression. Hence, the rat study as well as ours
does confirm the elevated expression of metallothionein.
Metallothioneins (MT) are ubiquitous, low molecular weight, intracellular zinc-binding
proteins with antioxidant properties. MT consists of 3 isoforms – MT1, MT2 and MT3.
We extracted the metallothionein 3 (MT3) pathway from Network 1 (see Figure 6).
Although the exact mechanism by which MT3 operates is not well known, there are a few
studies that have explained the possible roles of metallothionein, especially MT1 and
MT2. A recent study has shown that metallothioneins have positive effects during the
early phase of islet transplantation (34). Another study has shown that the
metallothionein gene is upregulated in wound margins particularly in regions of high
mitotic activity (35). These observations reflect its role in promoting cell proliferation
and re-epitheliation. Furthermore, selected growth factors may modulate metallothionein
gene expression and hence, the ability of cells to proliferate (35). As can be seen from
Figure 6, MT3 is connected to NF-KB1. In human fibroblasts, NFKB protein consisting
of p50 [NFKB1] and of p65 v-rel reticuloendotheliosis viral oncogene homolog A
(RELA) increases expression of human MT3 mRNA. There is also an indirect
relationship between MT3 and epidermal growth factor (EGF). EGF is involved in EGF
signalling, ephrin receptor signalling, neuregulin signalling, and NFKB signalling. EGF's
role in the cell is proliferation, migration, mitogenesis, apoptosis, growth, chemotaxis,
transformation, stimulation, S phase, and differentiation. Several other papers have also
shown that metallothionein positively regulates the cellular level and activity of NF-KB
(36, 37). Recent work by St. Croix et al (38), has also shown the protective role of
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metallothionein in acute lung injury. Cells deficient in MT1 and MT2 have shown
increased sensitivity to apoptosis (39). Other work suggests that under inflammatory
conditions, MT supports beneficial movement of leukocytes to the inflammation site
(40). In vitro experiments have shown that modest increase in MT levels still provides
protection against oxidative stress (41). All this research on MT suggests that it is a
valuable gene and should be analysed in extensive detail in the context of PGD.
Furthermore, whether the MT3 isoform has the same properties as MT1 and MT2 needs
to be determined. The overexpression of metallothionein 3 may protect the lung graft
from PGD. We feel that this is one of the most important insights into the mechanism of
PGD.
Classification of donor lungs using SVM:
The set of 100 ranked transcripts, obtained using RankGene, was used for the
classification of donor lungs into PGD positive and PGD negative classes by SVM. The
classification accuracy of SVM in differentiating the two classes was 70%. This indicates
that this set of transcripts has enough information to distinguish unsuitable and suitable
donor lungs.
The SVM did better at identifying the suitable lungs (i.e. low false negative). Considering
that the motivation behind using machine learning for the selection of suitable donor
lungs was to detect those that otherwise would have been discarded, this observation is
promising. The unsuitable donor lungs were more often misclassified and this can be
attributed to the fact that there were very few unsuitable donor lungs in the dataset (16
unsuitable lungs versus 34 suitable lungs) and subsequently, an even smaller number in
the training set. Furthermore, our dataset had been pre-selected by physicians based on
clinical criteria. Hence, the dataset did not have truly unsuitable donor lungs, i.e., lungs
considered unsuitable by clinical criteria. Obviously, certain lungs that passed the
selection criteria developed PGD. In essence, these were lungs that seemed to be good by
the current clinical criteria. Hence, the gene expression patterns of the unsuitable donor
lungs are very similar to the patterns of suitable lungs. In fact, when the gene expression
values of the DE transcripts were compared between PGD positive and PGD negative
lungs, the difference was marginal. These observations are not surprising as both sets of
lungs were considered suitable by clinical criteria, and therefore the difference between
them would be very subtle.
The SVM had difficulty in recognising some unsuitable donor lungs as it was not being
trained on the gene expression pattern of a large number of unsuitable donor lungs, or, for
that matter, on a large number of truly unsuitable donor lungs. Given the fact that we had
only 50 samples, in which we did not have truly unsuitable lungs, the classification
performance is good. Increasing the sample size in both categories would lead to a more
accurate and possibly larger set of DE transcript involved in PGD, as well as improved
classification results.
As the differences at the macroscopic level between PGD positive and PGD negative
donor lungs are minimised after employing the clinical selection criteria, gene expression
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profiling would help in amplifying whatever small differences there may be. SVMs are
capable of using these marginal differences to identify suitable and unsuitable donor
lungs. This is where machine learning plays a valuable role - assisting physicians and not
necessarily overruling them. Hence, machine learning methods, such as SVMs, can be
used in conjunction with clinical criteria to identify unsuitable donor lungs, thereby
further decreasing the chances of using donor lungs that would develop PGD. Due to the
limited dataset, it would be advantageous to have a larger dataset for further validation.
The study design affects the kind of questions that can be posed as well as the quality of
answers. As this was a pilot study to test the feasibility of the approaches, we restricted it
to only a few samples. Furthermore, we did not have enough tissue material to perform
RT-PCR to validate the microarray results. We hope that this research would motivate
and warrant the need for a larger study with more sophisticated statistical methods as well
as microarray validation tools. Moreover, an animal model would allow for more
samples to be taken at different time points which would further strengthen the study.
An interesting strategy would be to perform a random sampling of different regions of the
lung and subject it to microarray analysis. This was not done in this study due to three
reasons – 1) taking multiple samples from a donor lung when the primary objective is
transplantation is difficult to justify; 2) taking samples from different regions of the lung
necessitates the need for a larger sample set in order to reduce variance and increase
statistical power and finally 3) it was convenient to take a biopsy from the lingula or
anterior right middle lobe as opposed to other regions, without compromising the amount
of time the lung is kept without cold flushing. Due to the limited number of samples, we
could not perform an external validation and resorted to a 10-fold cross validation, which
is normal in many cases where SVM has been used for classification in a clinical study.
Furthermore, in order to improve the classification accuracy, it would be necessary to
include lungs in the training set that have been rejected by the clinical criteria. Although
we obtained 23 upregulated and 42 downregulated transcripts, only 13 of the 23 and 11 of
the 42 transcripts became focus genes in IPA. This indicates that the majority of the
transcripts do not have any specific function assigned to them as yet. Further research
into the functions of these transcripts will also provide some insight into their role in
PGD.

Conclusion
The incorporation of biological information into donor lung evaluation, based on studies
such as this one, may deem many of the excluded organs as suitable for transplantation,
directly impacting the mortality of patients on the lung transplant waiting list. Studies
show that 15-25% of patients develop clinically significant primary graft dysfunction
(PGD) after lung transplantation. PGD is the single most significant factor in determining
perioperative morbidity and mortality and has a devastating impact on outcome following
lung transplantation. It is the primary factor determining duration of mechanical
ventilatory support and length of ICU and hospital stay following lung transplantation.
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Perioperative mortality rates for those with clinically significant PGD are as high as 4060%. One year survival rates fall from 69% to 40% and 2-year rates from 66% to 27% in
those who suffer significant PGD. Furthermore, those that survive complications of PGD
endure lengthy hospitalisation periods and a protracted and often compromised recovery,
evidenced by inferior exercise tolerance and pulmonary function testing and the inability
to achieve independent lifestyles. Moreover, PGD is now being identified as a risk factor
for acute and chronic rejection.
In this study, gene expression profiling of donor lung samples was used to determine
gene products that are associated with the development of PGD after transplantation. It
also resulted in analysing possibly relevant pathways involved in PGD. When biological
markers were used to differentiate between PGD positive and PGD negative lungs, good
classification accuracy was achieved. The incorporation of biological markers into donor
organ evaluation will have a significant impact on outcomes after lung transplantation, by
potentially expanding the donor pool of organs selected for transplantation and by
identifying lungs at risk for the development of PGD post-transplant, which would allow
pre-treatment of these high risk organs or matching of these organs to relatively lower
risk recipients. Further identification and elucidation of genetic markers in donor lungs
associated with PGD could have a significant impact on lowering the incidence and
preventing the morbidity and mortality of PGD after lung transplantation. Our results
indicate that we have successfully achieved both our objectives.
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Table 1: Description of the upregulated transcripts from our DE list present in Network 1.
Table 2: Description of the downregulated transcripts from our DE list present in Network 2.
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TABLES
TABLE 1: Clinical Donor Characteristics
Characteristics
Age (years)
PaO2
Smoking history (years)
Gender
Cause of death
Marginal donors

PGD (n=16)
26.6 ± 8.9
406.7 ± 80.5
1.5 ± 2.07
71% M, 29% F
57% Trauma, 43% non-Trauma
1

No PGD (n=34)
24.0 ± 9.8
449.7 ± 80.0
2.9 ± 6.32
83% M, 17% F
75% Trauma, 25% non-Trauma
4

TABLE 2: Operative factors
Factors

PGD (n=16)

No PGD (n=34)

p value

Recipient diagnosis

32% COPD, 25% CF,
43% other

35% COPD, 32.5% CF,
32.5% other

0.98

Recipients with PPH

2

1

0.24

1st lung ischemic time
(min)

208.0 ± 44.0

240.0 ± 51.0

0.18

2nd lung ischemic time
(min)

330.0 ± 72.0

321.0 ± 51.0

0.69

Cardiopulmonary bypass
(CPB)

72%

17%

0.02

TABLE 3: Outcomes of patients with and without PGD
Outcome
Days on ventilator
ICU stay (days)
Total length of stay (days)
Perioperative mortality

PGD (n=16)
9.7 ± 11.7
11.3 ± 12.6
20.3 ± 13.0
28.5%

No PGD (n=34)
2.0 ± 3.7
2.9 ± 3.6
13.4 ± 8.1
0%
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p value
0.01
0.006
0.09
0.02

p value
0.53
0.17
0.59
0.78
0.66
0.99

TABLE 4: List of 81 differentially expressed transcripts output by SAM. There are 23
upregulated and 42 downregulated genes.
UP-regulated in PGD
negative lungs
Fold
Change

REFSEQ_MRNA

Gene Name

NM_005633
NM_000492

SON OF SEVENLESS HOMOLOG 1 (DROSOPHILA)
CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, ATP-BINDING
CASSETTE (SUB-FAMILY C, MEMBER 7)

NM_003645

FATTY-ACID-COENZYME A LIGASE, VERY LONG-CHAIN 1

1.7679424

NM_005573

LAMIN B1

1.6928441

NM_005502

ATP-BINDING CASSETTE, SUB-FAMILY A (ABC1), MEMBER 1

1.6240539

NM_017613

DOWNSTREAM NEIGHBOR OF SON

1.5424873

NM_019841

TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY V, MEMBER 5

1.5196761

NM_017760

LEUCINE ZIPPER PROTEIN 5

1.5172142

NM_018365

MEIOSIS-SPECIFIC NUCLEAR STRUCTURAL 1

1.5161006

NM_183419, NM_015435

RING FINGER PROTEIN 19

1.4642686

NM_015024

EXPORTIN 7

1.4545849

2.2183831
1.7822446

XM_938545

SIMILAR TO FORMIN-BINDING PROTEIN 3 (FORMIN-BINDING PROTEIN 11) (FBP 11)

1.3552737

NM_017654

STERILE ALPHA MOTIF DOMAIN CONTAINING 9

1.3251204

NM_016265

ZINC FINGER PROTEIN 12

1.2960459

NM_005531

INTERFERON, GAMMA-INDUCIBLE PROTEIN 16

1.2918867

NM_007358

METAL RESPONSE ELEMENT BINDING TRANSCRIPTION FACTOR 2

1.2824896

NM_005954

METALLOTHIONEIN 3 (GROWTH INHIBITORY FACTOR (NEUROTROPHIC))

1.2808244

NM_015205, NM_032189

ATPASE, CLASS VI, TYPE 11A

1.2417599

NM_007118
NM_001004420,
NM_001004419, NM_013269

TRIPLE FUNCTIONAL DOMAIN (PTPRF INTERACTING)

1.1514956

C-TYPE LECTIN DOMAIN FAMILY 2, MEMBER D

1.1469583

NM_181657

LEUKOTRIENE B4 RECEPTOR
SOLUTE CARRIER FAMILY 6 (NEUROTRANSMITTER TRANSPORTER, GABA),
MEMBER 11

1.1067929

NEUROPILIN 2

1.0625556

NM_014229
NM_201279, NM_003872,
NM_201266

1.0890867

Down-regulated in PGD
negative lungs
Fold
Change

REFSEQ_MRNA

Gene Name

NM_024917

CHROMOSOME X OPEN READING FRAME 34

2.3873841

NM_024508

ZINC FINGER, BED-TYPE CONTAINING 2

2.0313459

NM_022460
NM_178312, NM_178311,
NM_080920

HS1-BINDING PROTEIN 3

1.6525671

GAMMA-GLUTAMYLTRANSFERASE-LIKE ACTIVITY 4

1.5240059

NM_198544

1.5027289

NM_014241

CORTISTATIN
PROTEIN TYROSINE PHOSPHATASE-LIKE (PROLINE INSTEAD OF CATALYTIC
ARGININE), MEMBER A

NM_079837, NM_017869

BTG3 ASSOCIATED NUCLEAR PROTEIN

1.3943394

NM_025124

1.3593494

NM_001017962, NM_000917

HYPOTHETICAL PROTEIN FLJ21749
PROCOLLAGEN-PROLINE, 2-OXOGLUTARATE 4-DIOXYGENASE (PROLINE 4HYDROXYLASE), ALPHA POLYPEPTIDE I

NM_022337

RAB38, MEMBER RAS ONCOGENE FAMILY

1.3356873

NM_002035

FOLLICULAR LYMPHOMA VARIANT TRANSLOCATION 1

1.3315413

NM_024956

1.3201902

NM_003562

TRANSMEMBRANE PROTEIN 62
SOLUTE CARRIER FAMILY 25 (MITOCHONDRIAL CARRIER; OXOGLUTARATE
CARRIER), MEMBER 11

NM_007001

SOLUTE CARRIER FAMILY 35, MEMBER D2

1.3140864

1.4121977

1.3539779

1.3193721

XM_929985

SIMILAR TO LARGE SUBUNIT RIBOSOMAL PROTEIN L36A

1.3078617

NM_021029

RIBOSOMAL PROTEIN L36A

1.3078617

16

NM_019040

ELONGATION PROTEIN 4 HOMOLOG (S. CEREVISIAE)

1.2951361

NM_015654

N-ACETYLTRANSFERASE 9

1.2935561

NM_007069

1.2878168

XM_937648

HRAS-LIKE SUPPRESSOR 3
SIMILAR TO ALVEOLAR SOFT PART SARCOMA CHROMOSOME REGION,
CANDIDATE 1

NM_153741, NM_018973

DOLICHYL-PHOSPHATE MANNOSYLTRANSFERASE POLYPEPTIDE 3

1.2849801

NM_014320

HEME BINDING PROTEIN 2

1.2791263

NM_006476

ATP SYNTHASE, H+ TRANSPORTING, MITOCHONDRIAL F0 COMPLEX, SUBUNIT G

1.2710706

NM_002513

NON-METASTATIC CELLS 3, PROTEIN EXPRESSED IN

1.2675264

NM_018158

SOLUTE CARRIER FAMILY 4 (ANION EXCHANGER), MEMBER 1, ADAPTOR PROTEIN

1.2606948

NM_002213

INTEGRIN, BETA 5

1.2579474

NM_005865

PROTEASE, SERINE, 16 (THYMUS)

1.2495258

NM_020385

REX4, RNA EXONUCLEASE 4 HOMOLOG (S. CEREVISIAE)

1.2404477

NM_015958

DPH5 HOMOLOG (S. CEREVISIAE)

1.2402215

NM_021824

NIF3 NGG1 INTERACTING FACTOR 3-LIKE 1 (S. POMBE)

1.2392898

NM_014173, NM_001033549
NM_213622, NM_201647,
NM_006463

HSPC142 PROTEIN

1.2375188

STAM BINDING PROTEIN

1.2360276

NM_207356

CHROMOSOME 1 OPEN READING FRAME 174

1.2286265

NM_016142

HYDROXYSTEROID (17-BETA) DEHYDROGENASE 12

1.2277373

NM_016080

CHROMOSOME 17 OPEN READING FRAME 25

1.2263789

NM_080491, NM_012296

GRB2-ASSOCIATED BINDING PROTEIN 2

1.2246286

NM_032900

RHO GTPASE ACTIVATING PROTEIN 19

1.2229376

NM_004699

FAMILY WITH SEQUENCE SIMILARITY 50, MEMBER A

1.2086274

NM_003060

SOLUTE CARRIER FAMILY 22 (ORGANIC CATION TRANSPORTER), MEMBER 5

1.1931567

NM_014300

SEC11-LIKE 1 (S. CEREVISIAE)

1.1914145

NM_024766

CHROMOSOME 2 OPEN READING FRAME 34

1.1822266

NM_001004

RIBOSOMAL PROTEIN, LARGE, P2

1.1529057
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1.2864441

FIGURE LEGENDS
FIGURE 1: Sequence of analysis undertaken in this study. Gene expression profiling was conducted on 50
lung samples. The transcripts were ranked using RankGene in descending order of their t-statistic and the
top 100 were selected for further analysis. This set of 100 transcripts was used for classification by SVM
and resulted in an accuracy of 70%. The set of 100 transcripts was also analysed using SAM to determine
up and down regulated transcripts. SAM output 81 differentially expressed transcripts. After averaging the
values of and removing multiple probes mapping to the same gene name, 23 upregulated and 42
downregulated transcripts were obtained. Of the 23 upregulated transcripts, 13 became focus genes in IPA
and of the 42 downregulated, 11 were focus genes in IPA.

FIGURE 2: Network 1 - upregulated genes in PGD. This network primarily centres on tumour protein p53
(TP53). The focus genes are shown in

shaded/solid shapes. Further details on the focus genes are

provided in Table 4. The legend for this figure is Figure 7.

FIGURE 3: Network 1 with canonical pathways overlaid. The focus genes are shown in

shaded/solid

shapes. The location of the gene products is also indicated. Further details on the focus genes are provided
in Table 4. The legend for the figure is Figure 7.

FIGURE 4: Network 2 - downregulated genes in PGD. This network shows a lot of activity around beta-5
integrin (ITGB5) and GRB2-associated binding protein 2 (GAB2).

The focus genes are shown in

shaded/solid shapes. Further details on the focus genes are provided in Table 5. The legend for this
figure is Figure 7.

FIGURE 5: Network 2 with the canonical pathways overlaid.

The focus genes are shown in

shaded/solid shapes. The location of the different gene products is also depicted. Further details on the
focus genes are provided in Table 5. The legend for this figure is Figure 7.
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FIGURE 6: Network 3 - Metallothionein pathway. In human fibroblasts, NFKB protein consisting of p50
[NFKB1] and of p65 v-rel reticuloendotheliosis viral oncogene homolog A (RELA) increases expression of
human MT3 mRNA. The overexpression of metallothionein may protect the lung graft from PGD. The
legend for this figure is Figure 7.

FIGURE 7: Network Legend (a) Key for nodes in the network, (b) Key for edges in the network, (c) Key
for edge labels in the network
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